Construction of an Immune-Related Prognostic Signature and lncRNA‒miRNA–mRNA ceRNA Network in Acute Myeloid Leukaemia

Ling Qin,Boya Li,Shijie Wang,Yulai Tang,Aamir Fahira,Yanqi Kou,Tong Li,Zhigang Hu,Zunnan Huang

DOI: https://doi.org/10.1093/jleuko/qiae041

2024-02-23

Journal of Leukocyte Biology

Abstract:Abstract The progression of acute myeloid leukaemia (AML) is influenced by the immune microenvironment in the bone marrow and dysregulated intracellular competing endogenous RNA (ceRNA) networks. Our study utilized data from UCSC Xena, Cancer Genome Atlas Program, Gene Expression Omnibus, Immunology Database and Analysis Portal. Using Cox regression analysis, we identified an immune-related prognostic signature. Genomic analysis of prognostic mRNA was conducted through Gene Set Cancer Analysis (GSCA), and a prognostic ceRNA network was constructed using the Encyclopedia of RNA Interactomes. Correlations between signature mRNAs and immune cell infiltration, checkpoints, and drug sensitivity were assessed using R software, GEPIA, and CellMiner, respectively. Adhering to the ceRNA hypothesis, we established a potential lncRNA/miRNA/mRNA regulatory axis. Our findings pinpointed nine immune-related prognostic mRNAs (KIR2DL1, CSRP1, APOBEC3G, CKLF, PLXNC1, PNOC, ANGPT1, IL1R2, and IL3RA). GSCA analysis revealed the impact of copy number variations and methylation on AML. The ceRNA network comprised 14 differentially expressed prognostic lncRNAs (DE-lncRNAs), six prognostic DE-miRNAs, and three prognostic immune-related IR-DEmRNAs. Correlation analyses linked these mRNA's expression to 22 immune cell types, six immune checkpoints, and potential sensitivity to 27 antitumor drugs. Finally, we identified a potential LINC00963/hsa-miR-431-5p/CSRP1 axis. This study offers innovative insights for AML diagnosis and treatment through a novel immune-related signature and ceRNA axis. Identified novel biomarkers, including two mRNAs (CKLF, PNOC), one miRNA (hsa-miR-323a-3p), and ten lncRNAs (SNHG25, LINC01857, AL390728.6, AC127024.5, Z83843.1, AP002884.1, AC007038.1, AC112512, AC020659.1, AC005921.3) present promising candidates as potential targets for precision medicine, contributing to the ongoing advancements in the field.

immunology,cell biology,hematology

What problem does this paper attempt to address?

This paper attempts to address the impact of the immune microenvironment and competitive endogenous RNA (ceRNA) network on disease progression in acute myeloid leukemia (AML) and to construct an immune-related prognostic signature and ceRNA network. Specifically, the study utilized data from multiple databases, including UCSC Xena, The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and the Immunology Database and Analysis Portal (ImmPort). Through Cox regression analysis, the researchers identified an immune-related prognostic signature and performed genomic analysis of prognostic mRNAs using Gene Set Cancer Analysis (GSCA). Additionally, a ceRNA regulatory network comprising long non-coding RNA (lncRNA), miRNA, and mRNA was constructed.

The main objectives of the study are:
1. **Identify immune-related genes in AML**: Screen for differentially expressed genes between AML samples and healthy samples through differential expression analysis.
2. **Construct a prognostic signature**: Determine genes related to the survival of AML patients using Cox regression analysis and construct a prognostic signature.
3. **Analyze the immune microenvironment**: Evaluate the relationship between mRNAs in the prognostic signature and immune cell infiltration, immune checkpoints, and drug sensitivity.
4. **Explore potential ceRNA regulatory axes**: Identify possible lncRNA-miRNA-mRNA regulatory axes based on the ceRNA hypothesis to further understand the mechanisms of AML.

In summary, this study aims to provide new biomarkers and potential targets for the diagnosis and treatment of AML by constructing a novel immune-related prognostic signature and ceRNA network.